Pharmaceuticals, Biotechnology and Life Sciences
Horizon Discovery Group plc, the international life science company supplying research tools and services that power genomics research and the development of personalised medicines, has announced that its leveraged business unit has signed a programme in-licensing and option agreement with Servier, the independent French research-based pharmaceutical company .
Sanofi and its subsidiary Genzyme announced have that magnetic resonance imaging (MRI) data from the Phase III TEMSO study demonstrate that Aubagio (teriflunomide) significantly slowed brain volume loss (or atrophy) vs. placebo over two years in people with relapsing multiple sclerosis (RMS).
AstraZeneca has announced the global completion of the divestment of Caprelsa (vandetanib), a rare disease medicine, to Genzyme, a Sanofi company.
Watch a video and take a look at the U.S. government’s response in addressing Ebola in the United States.
Johnson & Johnson has announced the completion of the divestiture of its Cordis business to Cardinal Health for an approximate value of $2 billion, subject to customary adjustments.
AmerisourceBergen has announced that it has signed a definitive agreement to purchase PharMEDium Healthcare Holdings, Inc., the privately held provider of outsourced compounded sterile preparations (CSPs) to acute care hospitals in the United States, from Clayton, Dubilier & Rice for $2.575 billion in cash, subject to certain adjustments and on a cash-free, debt-free basis.
Akers Biosciences, Inc. a medical device company focused on reducing the cost of healthcare through faster, easier diagnostics, has announced that all development specifications have been finalized and production has commenced for its two transformational breath tests designed for the health and wellness industry and consumers.
Teva Pharmaceutical Industries Ltd. has announced that it has entered into definitive agreements under which the Company will acquire Representaciones e Investigaciones Médicas, S.A. de C.V. (Rimsa), a pharmaceutical manufacturing and distribution company in Mexico
Merck has announced the publication of results from C-SURFER, the first Phase 31 clinical trial to investigate an all-oral, ribavirin-free chronic hepatitis C virus (HCV) treatment regimen in treatment-naïve and treatment-experienced patients with advanced chronic kidney disease (CKD) stages 4 or 5 and chronic HCV genotype 1 (GT1) infection.
Alkermes plcp has announced that the U.S. Food and Drug Administration (FDA) has approved Aristadatm (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.